ライフサイエンスコーパス: PPI

1 PPI and AF showed better protein efficiency ratio and EA

2 PPI treatment reversed approximately 20% of the IL-13 tr

3 PPI use does not seem to cause significant changes in th

4 PPI use remains the dominant treatment, but long-term th

5 PPI use was associated with higher incidence of major fr

6 pooled-protein strategy to test all 318,096 PPI combinations.

7 of pH (8.0-1.5) and mixing ratio (1:1-30:1, PPI-pectin).

8 We predicted 50,220 PPIs in Arabidopsis thaliana, 13,175,414 PPIs in corn, a

9 Twenty-six papers (34 PPG trials and 29 PPI trials) were included.

10 oints for the development of specific 14-3-3 PPI stabilizers.

11 BEST PRACTICE ADVICE 4: PPIs have no therapeutic value in functional heartburn,

12 220 PPIs in Arabidopsis thaliana, 13,175,414 PPIs in corn, and 13,527,834 PPIs in soybean.

13 ide scaffold derived from the FGF14:Na(v)1.6 PPI interface.

14 Mapping >6000 PPIs shows that this network is extensively rewired in c

15 ana, 13,175,414 PPIs in corn, and 13,527,834 PPIs in soybean.

16 s protein families and constructed 5,879,879 PPIs in all organisms using ChiPPI.

17 h was strongly correlated (median: 0.98; 95% PPI: 0.66 to 0.98) with increases in testing.

18 ,689 (95% posterior predictive interval [95% PPI]: 1,023 to 14,182,310) infections occurred in the Un

19 A PPI network provides crucial information on how biologic

20 Seventeen (19%) patients were taking a PPI when the systemic reaction occurred (vs 5% in contro

21 ate, 68% of cases and 52% of controls used a PPI, and 16% of cases and 11% of controls used an H2RA.

22 Medication with a PPI is the most common treatment, and after initial full

23 However, there is growing concerns about PPI misuse, overuse and abuse.

24 g of amoxicillin, clarithromycin and PPI (AC/PPI).

25 entire sample and 45.3% vs. 66.8% in the AC/PPI-group.

26 g 52 aiHp to 52 non-aiHp cases within the AC/PPI-group.

27 and in 192 of 373 patients (51.5%) in the AC/PPI-group.

28 FD ("FD-starters") and HVs before and after PPI therapy (pantoprazole 40 mg once daily for 4 weeks).

29 FD ("FD-stoppers") before and 8 weeks after PPI withdrawal.

30 The effects of pH (7-2) and PPI-SBP mixing ratios (1:1-20:1) on coacervates formatio

31 = 0.76 +/- 0.42) (pH = 7) for caseinate and PPI, respectively.

32 onsisting of amoxicillin, clarithromycin and PPI (AC/PPI).

33 combination of Tregitope-albumin fusions and PPI peptides reduced the incidence of severe diabetes an

34 s the deficits in spatial working memory and PPI, presumably by restoration of synchronous GABA relea

35 GO enrichment analysis, KEGG pathways and PPI network indicated simultaneous utilization of leaf p

36 differences in the effects of LES on PPG and PPI responses compared with control interventions.

37 PPG and PPI responses were calculated as mean incremental area u

38 ake on the mean change difference in PPG and PPI were -0.02 mmol/L (95% CI: -0.09, 0.05) and -2.39 pm

39 l graph of drug-protein, disease-protein and PPIs.

40 dependent of pH(phi1) increased to pH 5.5 as PPI-SBP mixing ratio increased to 20:1.

41 We found strong association between PPI network modulation and adaptation to specific habita

42 nt studies have shown an association between PPI use and Alzheimer dementia, while others have disput

43 The associations between PPI use and fractures remained similar in analyses limit

44 Using STRING and BioGrid PPI databases, we compared the coherence of 116 phenotyp

45 nduced systemic reactions are facilitated by PPI, ingestion of large amounts of unprocessed foods, an

46 e genes in the EoE transcriptome reversed by PPIs.

47 s and benefits of prescribing and continuing PPIs in KTRs.

48 nd there has been little success controlling PPIs through standard molecular library screening approa

49 Among 3229 participants taking daily PPIs, 54.1% had persistent GERD symptoms.

50 Strategies to decrease PPI use and changes in the class of prophylactic antibio

51 thodology traditionally utilized to describe PPI, including that the underlying startle response has

52 enables us to validate previously described PPIs as well as to identify novel NS1 interactors.

53 ers that differentiate between two different PPI interfaces of the adapter protein 14-3-3.

54 itoring predicted the ability to discontinue PPIs without symptom escalation.

55 toring to predict the ability to discontinue PPIs.

56 Thirty-four participants (34%) discontinued PPIs.

57 d a 10 times increased odds of discontinuing PPI than participants with 4 days of AET > 4.0%.

58 500 mg) twice daily, with ongoing label-dose PPI.

59 y GERD, adding 1500 mg IW-3718 to label-dose PPIs significantly reduced heartburn symptoms compared w

60 ace, suggesting that even the most druggable PPI cavities are unlikely to be addressed with conventio

61 orrelated with eosinophils before and during PPI therapy, and increased eosinophils and permeability

62 ased on time-resolved luminescence, enabling PPI monitoring even at low nanomolar protein concentrati

63 ers, such as gastric ulcers and esophagitis, PPIs are now commonly used for prolonged durations and a

64 s, the list of host endogenous and exogenous PPIs that can be disrupted, and tissue expression of the

65 new reagents are still needed to help expand PPI coverage.

66 mixing ratios of 8:1, 8:1, 25:1 and 25:1 for PPI complexed with NP, MP42, MP37 and MP33, respectively

67 -mixing ratio of 8:1, 8:1, 10:1 and 15:1 for PPI with UM88, M72, M42, and M9, respectively.

68 roach to identify candidates appropriate for PPI cessation is not available.

69 referred to VA gastroenterology clinics for PPI-refractory heartburn, systematic workup revealed tru

70 atures of protein sequences are critical for PPI site prediction.

71 cle size than conjugation and was lowest for PPI-stabilized emulsions.

72 ploys a graph-based deep learning method for PPI prediction, which shows superiority over existing se

73 Extraction method for PPI was optimized by varying NaCl (0, 0.5, 1 M) and flou

74 nd global sequence features, is proposed for PPI site prediction.

75 hods have traditionally been widely used for PPI studies, label-free techniques have recently drawn s

76 tilized to automatically learn features from PPI network.

77 atically reconstruct signaling pathways from PPIs that leverages cellular localization information ab

78 Furthermore, PPI treatment decreased the IL-13-induced proliferative

79 s in markers of bone turnover in women given PPI therapy compared with women given placebo, but level

80 ional biological experiments for identifying PPI sites are costly and time-consuming.

81 hat the experimental methods for identifying PPIs are time-consuming and expensive, it is important t

82 Immutable PPIs aggregate into highly connected 'core' network modu

83 A few 'immutable' PPIs are present across all conditions, while most 'muta

84 ests that Maillard conjugation could improve PPI emulsification properties.

85 d networks, which were semantically improved PPI networks, showed better performances by having highe

86 odel, we find no evidence for differences in PPI in a rat model of Fragile-X Syndrome (FXS) compared

87 a graph has been proved to be informative in PPI prediction.

88 Procedures were also performed in PPI-refractory patients with FD ("FD-stoppers") before a

89 to rapidly identify the domains involved in PPIs by advancing the use of yeast two-hybrid technology

90 xygenase and the free radical populations in PPIs were positively related to the overall beany-relate

91 In total, 67 volatiles in PPIs were identified via HS-SPME-GC-MS/O.

92 urgitation, and/or chest pain and inadequate PPI response.

93 nts with typical reflux symptoms, inadequate PPI response, and absence of severe esophagitis, acid ex

94 y that could be used to clarify inconsistent PPI results in mice and humans.

95 Clinicians should individualize PPI use in KTRs, evaluating the risks and benefits of pr

96 Peptidomimetics have been applied to inhibit PPIs, however with variable success, as for certain inte

97 ng (FC), a reduction in prepulse inhibition (PPI) in the KO animal, along with a deterioration in mem

98 tial working memory and prepulse inhibition (PPI) of acoustic startle in Grin1 mutant mice.

99 omotion and changes in pre-pulse inhibition (PPI).

100 e, but the effects of proton pump inhibitor (PPI) drugs are incompletely characterized.

101 Proton pump inhibitor (PPI) therapy fails to provide adequate symptom control i

102 maximal (double-dose) proton pump inhibitor (PPI) therapy taken appropriately before meals during a 3

103 15.0; P = 0.011), and proton pump inhibitor (PPI) use (OR, 3.50; 95% CI, 1.19 to 10.3; P = 0.023) wer

104 ed empirically with a proton pump inhibitor (PPI).

105 Proton pump inhibitors (PPIs) are frequently used after kidney transplantation a

106 Proton pump inhibitors (PPIs) are used for the long-term treatment of gastroesop

107 Proton pump inhibitors (PPIs) have been recognized as a primary treatment of eos

108 ect and mechanism of proton pump inhibitors (PPIs) or first-line therapy remain unclear.

109 Proton pump inhibitors (PPIs) or histamine-2 receptor blockers (H2RBs) are often

110 o receive label-dose proton pump inhibitors (PPIs) still have symptoms.

111 Proton pump inhibitors (PPIs), which are commonly used as inhibitors of gastric

112 ptoms despite use of proton pump inhibitors (PPIs).

113 erval [CI] 1.5-4.7), proton pump inhibitors (PPIs; OR 2.1, 95% CI 1.3-3.4), and exposure to third- (O

114 Proton-pump inhibitors, PPIs, are considered effective therapy for stomach acid

115 dial glucose (PPG) and postprandial insulin (PPI) responses, in order to comprehensively and objectiv

116 eases using the Protein-Protein Interaction (PPI) and gene-disease heterogeneous networks.

117 -helix-mediated protein-protein interaction (PPI) complex structures.

118 ling of a model protein-protein interaction (PPI) in vitro.

119 eir function as protein-protein interaction (PPI) inhibitors.

120 the PEX14-PEX5 protein-protein interaction (PPI) is an attractive way to affect multiple metabolic p

121 work for binary protein-protein interaction (PPI) mapping based on optimally combining assays and/or

122 we performed a protein-protein interaction (PPI) network analysis of known intraflagellar transport,

123 enrichment and protein-protein interaction (PPI) network analysis.

124 uated through a protein-protein interaction (PPI) network combined with a co-expression network.

125 al structure in protein-protein interaction (PPI) network data that might mean that alternate methods

126 etworks such as protein-protein interaction (PPI) network, gene co-expression (CE) network and pathwa

127 to construct a protein-protein interaction (PPI) network, then the modules in the PPI networks were

128 es in the whole protein-protein interaction (PPI) network.

129 quence data and protein-protein interaction (PPI) network.

130 Protein-protein interaction (PPI) networks are frequently used to predict disease gen

131 haracterize how protein-protein interaction (PPI) networks change, we quantified the relative PPI abu

132 cally, we built protein-protein interaction (PPI) networks with proteins encoded by AD- and psychosis

133 we find altered protein-protein interaction (PPI) of mGluR5 with RGS4, norbin, Preso 1 and tamalin, w

134 DI) prediction, protein-protein interaction (PPI) prediction; and 2 node classification tasks: medica

135 ctions, such as protein-protein interaction (PPI), remains to be elucidated.

136 ns by reporting protein-protein interaction (PPI)-dependent, mutation-specific, and drug-driven chang

137 lex network of protein-protein interactions (PPI).

138 l for defining protein-protein interactions (PPIs) and elucidating architectures of large protein ass

139 e stability of protein-protein interactions (PPIs) and impact their functions, which may cause variou

140 Protein-protein interactions (PPIs) are an essential part of correct cellular function

141 Protein-protein interactions (PPIs) are central to many biological processes.

142 Protein-protein interactions (PPIs) are fundamental in many biological processes and u

143 Protein-protein interactions (PPIs) are involved in many of life's essential biologica

144 Disruption of protein-protein interactions (PPIs) between Na(v)1.6 and fibroblast growth factor 14 (

145 prediction of protein-protein interactions (PPIs) between the host and a microbial species, includin

146 Protein-protein interactions (PPIs) control many important physiological processes wit

147 abilization of protein-protein interactions (PPIs) holds great potential for therapeutic agents, as i

148 abilization of protein-protein interactions (PPIs) is a promising strategy for drug discovery.

149 examination of protein-protein interactions (PPIs) is fundamental for the understanding of cellular m

150 complexity of protein-protein interactions (PPIs) is further compounded by the fact that an average

151 Cell-surface protein-protein interactions (PPIs) mediate cell-cell communication, recognition, and

152 the predicted protein-protein interactions (PPIs) of all gene products, including those of stress-re

153 Protein-protein interactions (PPIs) play essential roles in many biological processes.

154 Protein-protein interactions (PPIs) play important roles in many biological processes.

155 mic virus-host protein-protein interactions (PPIs) that are intrinsic to the spread of infections.

156 ctions through protein-protein interactions (PPIs) with client proteins.

157 evaluate these protein-protein interactions (PPIs), such as in vitro pull downs and coimmunoprecipita

158 s to redesign the protein-protein interface (PPI) of the c-Raf-RBD:KRas complex.

159 coacervation between a pea protein isolate (PPI) and each pectin was investigated as a function of p

160 unctional properties of the protein isolate (PPI) and protein fractions from pumpkin seed were evalua

161 lex coacervates between pea protein isolate (PPI) and sugar beet pectin (SBP) at concentrated solutio

162 In this study, pulse protein isolates (PPIs) were extracted from 0, 1, 3, and 5 days germinated

163 Known PPIs of ciliary proteins were assembled from online data

164 onsists of 165 ciliary proteins, 1,011 known PPIs, and 765 novel PPIs.

165 ncer biology based on published literatures, PPI-network and large-scale omics data.

166 eria when heartburn persists despite maximal PPI therapy in patients with history of proven GERD (ie,

167 As demonstrated with p53-MDM2 PPI as a model application, the right-handed d-sulfono-g

168 ical side chains of p53 and disrupt p53/MDM2 PPI effectively.

169 Treatments include lifestyle modification, PPI medication, and laparoscopic fundoplication.

170 Developing molecules that modulate PPIs through the interface of their protein surfaces has

171 One-month PPI treatment significantly decreased NOX5, mPGES1 and i

172 Moreover, PPI networks suffer from network quality issues, which c

173 Most PPIs occur through small domains or motifs, which are ch

174 Mutable PPIs are less likely to co-express, co-localize, and be

175 across all conditions, while most 'mutable' PPIs are rarely observed.

176 stabilization of native PPIs, and non-native PPIs have received little consideration.

177 entification and stabilization of non-native PPIs of N protein could be applied toward drug discovery

178 ainly focused on the stabilization of native PPIs, and non-native PPIs have received little considera

179 New PPIs include proteins expressed on multiple cell types a

180 We identified new PPIs for receptors with well-characterized ligands and b

181 of hyperdopaminergia, as well as normalizing PPI in DATKO mice.

182 Novel PPIs were predicted for each ciliary protein using a com

183 ry proteins, 1,011 known PPIs, and 765 novel PPIs.

184 Observed PPIs reveal a large and complex network of interactions

185 y structure mimetics as an emerging class of PPI modulators.

186 Systematic comparison of PPI cavities with pockets deduced from druggable protein

187 Complexation of PPI with NP and MP42 greatly improved the protein solubi

188 ing, but not the sound-scaling, component of PPI.

189 rtle-scaling and sound-scaling components of PPI are a function of the baseline startle response.

190 f D2R clusters associated with a decrease of PPI.

191 Our objective was to identify the effects of PPI use on the microbial community of the esophagus.

192 We also found that half of PPI users have persistent symptoms.

193 ility for high-throughput screening (HTS) of PPI inhibitors.

194 duced systemic reactions were independent of PPI treatment.

195 Structural information of PPI networks such as their degree, position, and neighbo

196 while ignoring the structural information of PPI networks.

197 Here, we deconstruct the phenomenon of PPI and confirm several limitations of the methodology t

198 The strongest predictor of PPI discontinuation was number of days with acid exposur

199 SDS-PAGE profile of PPI revealed major bands ranging from 50 to 7 kDa.

200 nsively for this purpose, but the results of PPI studies are often inconsistent.

201 Primary outcome was tolerance of PPI cessation (discontinued or resumed PPIs).

202 l to examine the effects of long-term use of PPI in vivo.

203 gible impact on the proximate composition of PPIs.

204 methodologies often prevent the detection of PPIs with low abundance proteins.

205 The therapeutic effectiveness of PPIs associated with a lack of toxicity indicates that t

206 These results demonstrate broad effects of PPIs on esophageal epithelium, including their ability t

207 tional design of small molecule enhancers of PPIs remains elusive.

208 lel experimentation for the investigation of PPIs.

209 ducing effects as a therapeutic mechanism of PPIs in FD, with differential effects in HVs pointing to

210 The modulation of PPIs presents opportunities to gain mechanistic insights

211 ternative strategy to antagonize a myriad of PPIs.

212 7), contributed to the beany-related odor of PPIs but much less than that in raw flours.

213 However, the overall beany-related odor of PPIs increased when the germination time exceeded 1 day.

214 ifficulties associated with the targeting of PPIs, in particular when extended and flat protein inter

215 e sequence with use of H2RBs and then use of PPIs (13 436 patients randomized by site to PPIs and 13

216 Use of PPIs and histamine 2-receptor antagonists (H2RA) during

217 were randomized to the sequence with use of PPIs and then use of H2RBs and 25 ICUs were randomized t

218 The use of PPIs led to a significant difference in absolute levels

219 Use of PPIs, but not H2RAs, is associated with a higher risk of

220 Patient demographics, use of PPIs, duration of use and dose were recorded.

221 major motor disorders, and pH monitoring off PPI therapy (or pH-impedance monitoring on therapy in pa

222 nt prolonged wireless reflux monitoring (off PPIs for >=7 days) and a 3-week PPI cessation interventi

223 mune cells also decreased in FD-stoppers off PPIs.

224 ophageal ulcer), and pH impedance testing on PPI therapy demonstrates physiologic acid exposure witho

225 symptoms were currently on therapy (55.2% on PPIs, 24.3% on histamine-2 receptor blockers, and 24.4%

226 nd to cluster according to habitat, based on PPIs rather than on sequence similarities.

227 eased eosinophils and permeability in HVs on PPIs were associated with changes in bile salts.

228 e cells and permeability increased in HVs on PPIs.

229 Ninety percent (52/58) of patients were on PPIs.

230 Although a proportion do not require ongoing PPI therapy, a diagnostic approach to identify candidate

231 ing acute postprandial effects on PPG and/or PPI after exposure to LES, either alone, with a meal, or

232 764 pairwise PPIs, a threefold increase over PPIs identified in one condition.

233 -condition screen identified 13,764 pairwise PPIs, a threefold increase over PPIs identified in one c

234 st line of compounds that inhibit PEX14-PEX5 PPI.

235 l method we developed, called High-precision PPI Prediction (HiPPIP) model.

236 lly use local contextual features to predict PPI sites.

237 nal approaches have been proposed to predict PPI sites.

238 al sequence features are combined to predict PPI sites.

239 ated computational methods to better predict PPIs.

240 products) in combination with preproinsulin (PPI) target antigen peptides.

241 tified 5-benzyloxygramine as a new N protein PPI orthosteric stabilizer that exhibits both antiviral

242 terize Maillard conjugates from pea protein (PPI) or caseinate and dextran, and to evaluate the physi

243 mized by ICU site to H2RBs actually received PPIs.

244 KI and wild-type mice received PPIs or PBS intraperitoneally and were analyzed for surv

245 inhibition of the acoustic startling reflex (PPI; a marker of psychotic-like behavior), memory, locom

246 networks change, we quantified the relative PPI abundance of 1.6 million protein pairs in the yeast

247 inhibition of the acoustic startle response (PPI) is a behavioral phenomenon studied extensively for

248 reater among the discontinued versus resumed PPI group (RESQ-eD, -43.7% vs -5.3%; P = .04).

249 ce of PPI cessation (discontinued or resumed PPIs).

250 We then develop a novel model that reveals PPI to be a combination of the previously appreciated sc

251 Our model can study PPI prediction based on both sequence information and gr

252 These methods are ideal for studying PPIs, most importantly as there is no need for labeling

253 proach to overcome the hurdles in systematic PPI stabilizer discovery.

254 days in past week) among participants taking PPIs.

255 to have continued symptoms, even when taking PPIs.

256 Targeting PPIs associated with Mcl-1 presents many challenges for

257 rging, which may reduce the use of long-term PPI and fundoplication, but the long-term safety and eff

258 After long-term PPI exposure, the fecal microbial profile was altered an

259 tabolic change are consequences of long-term PPI exposure.

260 sted several adverse effects after long-term PPI, but these findings need to be confirmed before infl

261 racteristic and precision-recall curves than PPI networks for both zebrafish and mouse.

262 We hypothesized that PPIs can counteract IL-13-mediated esophageal epithelial

263 with MCODE and the hub genes chose from the PPI networks were verified by Oncomine and TCGA database

264 ysis; 2459 of 13 415 patients (18.3%) in the PPI group died at the hospital by day 90 and 2333 of 13

265 c reaction) was reported in 1 patient in the PPI group.

266 ction (PPI) network, then the modules in the PPI networks were analyzed with MCODE and the hub genes

267 ect of 41 different sets of mutations in the PPI of the c-Raf-RBD:KRas complex.

268 In addition, it leverages the PPI network and Gene Ontology structure to further coord

269 ointestinal bleeding occurred in 1.3% of the PPI group and 1.8% of the H2RB group (risk ratio, 0.73 [

270 this integration improves the quality of the PPI networks by reducing the number of false positive an

271 To offset the statistical limits of the PPI structure and sequence databases, amino acid-specifi

272 Functional analysis of the PPI-responsive, upregulated genes revealed enrichment in

273 s of human esophageal cells to IL-13 and the PPIs omeprazole and esomeprazole were assessed by RT-PCR

274 These PPIs provide a resource for further biological investiga

275 This possibility suggests that these PPIs, and perhaps not the individual chaperones themselv

276 subnetworks affected by blast fungus through PPIs were investigated.

277 8, a bile acid sequestrant, as an adjunct to PPI therapy.

278 enal and systemic alterations in relation to PPI therapy in patients with FD and healthy volunteers (

279 ageal epithelial cells robustly responded to PPI stimulation by inducing a set of 479 core genes comm

280 ng 79 SOT recipients (7.3%), and exposure to PPIs (OR 2.4, 95% CI 1.1-5.4) and third-generation cepha

281 The transcriptional response to PPIs was partially mediated through the aryl hydrocarbon

282 nderlying esophageal epithelial responses to PPIs remain poorly understood.

283 d 4.1% of patients randomized by ICU site to PPIs actually received H2RBs and an estimated 20.1% of p

284 PPIs (13 436 patients randomized by site to PPIs and 13 392 randomized by site to H2RBs).

285 ssian distribution, and that the traditional PPI metric changes with different stimuli.

286 heartburn, systematic workup revealed truly PPI-refractory and reflux-related heartburn in a minorit

287 reconstruction algorithms are applied to two PPI networks and assessed using both global and local de

288 g off acid suppression can limit unnecessary PPI use and guide personalized management.

289 nalysis, revealed ~380 previously unreported PPIs.

290 ains, which provides insights into utilizing PPI for improved DR assessment.

291 cs of host-host, virus-host, and virus-virus PPIs.

292 itoring (off PPIs for >=7 days) and a 3-week PPI cessation intervention.

293 This study aimed to determine whether PPI use is associated with incidence of major fractures

294 f new therapies are needed for patients with PPI-refractory GERD symptoms.

295 igher in FD-starters vs HVs and reduced with PPI therapy.

296 ut gene-anatomical entity relationships with PPI networks using anatomy ontology annotations.

297 ut gene-anatomical entity relationships with PPI networks via anatomy ontology improved the candidate

298 Treatment of KI mice with PPIs had a clear clinical effect, showing a reduction in

299 ategies were compared (preferential use with PPIs vs preferential use with H2RBs).

300 as well as a classical version of the yeast PPI network in rigorous cross validation experiments.

301 based gene networks with mouse and zebrafish PPI networks retrieved from the STRING database and comp